PubMed Trending Research Digest — July 14, 2026

Automated digest · 95 articles · 15 research areas · July 14, 2026

Overview

Across this week’s PubMed highlights, a dominant thread is the move toward mechanism-driven, measurable biomarkers—spanning neurodegeneration, cancer, and metabolic disease. In neurobiology, studies link specific molecular pathways (e.g., HIV-1 Tat–driven NMDAR/cAMP/PKA control of astrocytic AQP4) and imaging/AI-derived metrics (retinal fluid volume segmentation; diffusion MRI cerebrovascular trajectories) to clinically meaningful outcomes. In cancer, multiple efforts refine how we interpret and deploy biomarkers: ctDNA mutation calling beyond variant allele fraction limits, proteomic/immune signatures for risk stratification, and computational pipelines (e.g., TIPs) that expand antigen discovery for immunotherapy.

A second major theme is targeted intervention—often “precision” in delivery or patient selection—rather than one-size-fits-all treatment. Examples include focused ultrasound–mediated BBB modulation to stimulate endogenous oligodendrogenesis, engineered oral nanovesicles/probiotics for IBD, and advanced cell therapy engineering (CAR γδ T-cell performance tradeoffs; proposed Lu-177 PSMA–CAR T combinations to overcome solid-tumor immune suppression). In cardiometabolic care, real-world and trial-adjacent evidence continues to test modern drug strategies (SGLT2i in cardiac amyloidosis; GLP-1RA vs DPP-4i comparisons in dialysis and add-on strategies after empagliflozin), while mechanistic work in liver disease and ferroptosis (immune–hepatocyte signaling axes) points to next-generation therapeutic targets for MASH/MASLD.

Finally, several studies emphasize immune and inflammatory control across diverse settings—from reproductive immunology in ART-associated placental dysfunction to immune-mediated toxicities of cancer therapies (e.g., “triple M” overlap after immune checkpoint inhibitors) and autoimmune relapse prevention in MOGAD. Together, these articles reflect a broader shift toward integrating biology, imaging/omics, and real-world evidence to improve prediction, reduce harm, and tailor therapies to the right patients and pathways.

---

Neuroregeneration & Brain Barrier Modulation

Shared Genetic Architecture and Multidimensional Modifiable Correlates between Myopia and Retinal-Optic Nerve Diseases.

This genetic pleiotropy and population-based cohort study investigated shared genetic architecture and modifiable correlates between myopia and retinal-optic nerve diseases (RONDs) using 81,491 UK Biobank participants plus large-scale GWAS summary statistics. The key finding was evidence of cross-trait genetic overlap between myopia and multiple RONDs, supported by locus-level annotation, colocalization, and enrichment analyses. Scientifically, it identifies shared biological pathways and potential modifiable factors that could inform risk stratification and prevention strategies for retinal-optic nerve complications in myopia.

Gao Y, Xu J, Yu J et al. · Ophthalmology science · (2026) · View on PubMed ↗ · Free PDF ↗

Smart-responsive electrospun scaffolds (SRES) for neural repair: Recent advances and future prospects.

This review summarized smart-responsive electrospun scaffolds (SRES) for neural repair, focusing on how engineered scaffold properties can address limitations of current interventions after neurological injury. It reports that SRES can be designed to respond to injury-relevant cues (e.g., to modulate cell behavior and support regeneration) to mitigate challenges such as weak central neuron regeneration and glial scar formation. The significance lies in consolidating design principles and future prospects for next-generation tissue-engineered implants to reconstruct damaged neural circuits.

Shen H, Jia M, Zhu H et al. · Bioactive materials · (2026) · View on PubMed ↗ · Free PDF ↗

The modulation of the blood-brain barrier by focused ultrasound stimulates oligodendrogenesis.

The study investigated whether focused ultrasound (FUS)–mediated blood-brain barrier (BBB) modulation using intravenous microbubbles stimulates oligodendrogenesis in adult mice, with unilateral targeting to the hippocampus. FUS-BBB modulation increased oligodendrocyte precursor cell (OPC) proliferation and promoted downstream oligodendrogenic/myelination-related regenerative processes. These findings suggest a noninvasive, drug-free neuromodulation strategy to enhance white-matter repair by driving endogenous oligodendrogenesis.

Noseworthy K, Silburt J, Apa A et al. · Acta neuropathologica communications · (2026) · View on PubMed ↗

---

Neuroinflammation, Neurotoxicity & Neurodegeneration Mechanisms

Proteomics of post mortem brains in early- and late-onset Alzheimer’s disease: Unraveling differential Aβ effects and potential AD biomarkers.

This study used mass spectrometry proteomics on 115 post-mortem temporal lobe samples to compare early-onset Alzheimer’s disease (EOAD) and late-onset Alzheimer’s disease (LOAD) while assessing differential amyloid beta (Aβ) effects using a dedicated AD spectral library. It found AD-associated downregulation of mitochondrial and synaptic pathways with upregulation of immune and small-molecule metabolic processes, with larger fold changes in EOAD, and identified elevated AD biomarker signals including multi-phosphorylated species. These proteomic differences and biomarker candidates may help distinguish EOAD versus LOAD biology and improve biomarker development for Alzheimer’s disease.

Thanou E, Ganz A, Pita-Illobre D et al. · Alzheimer’s & dementia : the journal of the Alzheimer’s Association · (2026) · View on PubMed ↗ · Free PDF ↗

Clinicopathologic Evaluation of Amyloid Clearance in Alzheimer Disease.

This JAMA clinicopathologic case report studied a male Alzheimer disease carrier of the p.R47H TREM2 variant, examining postmortem and in vivo relationships between amyloid clearance and downstream tau pathology/neurodegeneration after treatment with aducanumab. The key finding was that in a patient with patchy minimal residual amyloid, amyloid clearance could be assessed alongside downstream neuropathologic changes, linking amyloid reduction to later tau/neurodegenerative processes. Scientifically, the case provides mechanistic context for how amyloid-targeting therapy may influence tau pathology, informing interpretation of anti-amyloid treatment efficacy.

Brown CA, Robinson JL, Das SR et al. · JAMA · (2026) · View on PubMed ↗

Regulation of AQP4 Expression and Investigation of the Underlying Mechanisms by HIV-1 Tat Through the NMDAR/cAMP/PKA Signaling Pathway in Astrocytes.

This study investigated how HIV-1 Tat regulates aquaporin-4 (AQP4) expression in astrocytes via the NMDAR/CaMKII/AC/cAMP/PKA signaling pathway. The key finding was that Tat-driven NMDAR signaling and downstream Ca2+-dependent cAMP/PKA activation modulate AQP4 expression in astrocytes. These mechanistic results support a specific neurotoxicity pathway for HAND and suggest NMDAR–cAMP/PKA signaling as a potential therapeutic target to limit astrocytic water-channel dysregulation.

Li C, Duan R, Fu C · Iranian journal of allergy, asthma, and immunology · (2026) · View on PubMed ↗ · Free PDF ↗

Development of an in vivo, screenable, split-luciferase based model of huntingtin multimerization.

This work developed an in vivo, screenable split-luciferase model (HTTLUM) to study huntingtin (HTT) multimerization driven by polyglutamine (polyQ) expansion in Huntington’s disease. The key advance is a split-luciferase-based readout that enables detection of HTT multimerization species in vivo for unbiased screening of genetic modifiers and pharmacological strategies that suppress aggregation or inclusion body formation. This is scientifically significant because it provides a tractable platform to accelerate discovery of interventions targeting HTT aggregation dynamics.

Thomas MG, Levy SA, Jenkins MH et al. · iScience · (2026) · View on PubMed ↗ · Free PDF ↗

Neuroimaging evidence of mitochondrial dysfunction and inflammation in psychiatric disorders: a review.

This review synthesized neuroimaging evidence for mitochondrial dysfunction and neuroinflammation across psychiatric disorders, focusing on multimodal techniques such as magnetic resonance spectroscopy, mitochondrial-complex PET tracers, TSPO PET, and emerging targets including C3aR/IL-1β. It summarizes how these imaging modalities can measure mitochondrial metabolic processes and inflammatory signaling in vivo. The review is significant for guiding future biomarker-driven studies that connect mitochondrial and immune mechanisms to psychiatric disease progression.

Li J, Ma X, Liu J et al. · Psychoradiology · (2026) · View on PubMed ↗ · Free PDF ↗

---

Neuroimaging Biomarkers & AI/Imaging Analytics

Plasma Phosphorylated Tau 217 in Participants at Risk for Chronic Traumatic Encephalopathy.

This longitudinal multicenter case-control study assessed plasma phosphorylated tau 217 (p-tau217) in participants with repetitive head impact (RHI) exposure at risk for chronic traumatic encephalopathy (CTE) using data from the DIAGNOSE CTE project (September 2016–October 2023). It evaluated p-tau217’s utility as an in vivo biomarker, including performance as a beta-amyloid (Aβ) biomarker and concordance with CTE neuropathology in a postmortem subsample. The work is significant because it tests whether a blood-based tau biomarker can support detection of CTE-related neuropathology in at-risk individuals.

Miner AE, Zetterberg H, Blennow K et al. · JAMA network open · (2026) · View on PubMed ↗ · Free PDF ↗

Age, Multidomain Lifestyle Intervention, and White Matter Integrity: Secondary Analysis of the POINTER Randomized Clinical Trial.

This secondary analysis of the POINTER randomized clinical trial studied how age and a multidomain lifestyle intervention affected cerebrovascular injury trajectories using diffusion MRI and other white matter integrity measures in at-risk older adults. It found whether the intervention altered cerebrovascular MRI marker progression differently by age and how baseline diffusion MRI estimates subsequent vascular injury. The significance is that it clarifies which imaging biomarkers and age strata may identify who benefits most from lifestyle-based strategies to slow cognitive decline.

Maillard P, Vemuri P, Harvey DJ et al. · JAMA network open · (2026) · View on PubMed ↗ · Free PDF ↗

Social network characteristics and cognitive function, decline, and mortality: A joint modeling approach.

This joint modeling analysis studied whether social network characteristics relate to cognitive function, cognitive decline, and mortality in adults aged ≥90 years (n=677) from the multi-ethnic LifeAfter90 Study, with effects examined by sex/gender. Over 1.63 years of follow-up (163 deaths), baseline social network structural and functional measures were associated with subsequent cognitive trajectories and mortality (details truncated in the abstract). The findings suggest that social network features may be clinically relevant risk markers for late-life cognitive decline and survival, potentially informing interventions in very old populations.

Chen R, Posis AIB, Pederson AM et al. · Alzheimer’s & dementia : the journal of the Alzheimer’s Association · (2026) · View on PubMed ↗ · Free PDF ↗

Assessment of treatment response in recurrent medulloblastoma using craniospinal MRI.

This retrospective imaging study assessed whether quantitative craniospinal MRI measures of baseline tumor burden predict outcomes in 40 patients with recurrent, previously irradiated medulloblastoma treated with MEMMAT (metronomic antiangiogenic) therapy. Lesion count and volume from manually segmented ependymal, leptomeningeal, and local relapse lesions on T1-contrast-enhanced (T1CE) and diffusion-weighted imaging (DWI) at baseline and follow-up were evaluated for prognostic value. If validated, quantitative craniospinal MRI metrics could improve response assessment and risk stratification in recurrent medulloblastoma undergoing MEMMAT.

Hennenberg J, Hofer L, Nemeth B et al. · European journal of radiology · (2026) · View on PubMed ↗ · Free PDF ↗

Structural and Functional Neuroimaging Findings in Fibromyalgia: A Systematic Review.

This systematic review synthesized structural and functional neuroimaging studies in adults with fibromyalgia (FM) compared with healthy controls to identify the most reproducible cross-modal brain alterations. It found that neuroimaging results across modalities are inconsistent, and the review aimed to determine which findings are most reproducible across study designs and analysis methods. The clinical significance is that consolidating reproducible imaging signatures could improve understanding of central nervous system involvement and guide future biomarker development in FM.

Flutt FAD, de Melo Cortez JP, Ramos LR et al. · European journal of pain (London, England) · (2026) · View on PubMed ↗ · Free PDF ↗

Quantitative Analysis of Retinal Fluid by a Deep Learning Model in Uveitic Macular Edema.

This secondary analysis studied whether deep learning–derived quantitative retinal fluid volume predicts visual outcomes in uveitic macular edema (UME) and compared it with central macular thickness (CMT) alone. The key finding was that an AI segmentation approach using a 2D U-Net model (trained on age-related macular degeneration and retinal vein occlusion data) can provide prognostic information for UME outcomes beyond CMT measurements. This is significant because it advances objective, scalable imaging biomarkers for monitoring and predicting vision in noninfectious uveitis treated in the FAST trial.

Wu A, Au A, Hanson J et al. · Ophthalmology science · (2026) · View on PubMed ↗ · Free PDF ↗

---

Neurodevelopmental/Circadian & Sleep Biology

Biological limits of lifespan extension: evidence for a shift from pathway leverage to system-level buffering across species.

This comparative mechanistic analysis investigated why lifespan extension from conserved aging pathway interventions shows diminishing returns with increasing organismal complexity. The authors propose a shift from pathway “leverage” in simple organisms to system-level buffering in mammals, characterized by redundancy, feedback, and competing physiological constraints. This framework clarifies biological limits on lifespan extension and guides how future interventions should be designed across species.

Pirscoveanu DF, Papa MC, Kaltwasser B et al. · Mechanisms of ageing and development · (2026) · View on PubMed ↗

The gut-sleep connection: a scoping review into microbiome alterations in sleep-wake and circadian disorders.

This scoping review summarized evidence linking gut microbiome alterations to sleep duration, sleep loss, sleep-wake disorders, and circadian rhythm-related phenotypes. Across 54 included studies (observational, interventional, and genome-wide association/Mendelian-randomization), the review reports microbiome changes associated with sleep and circadian disturbances. The synthesis supports further mechanistic and interventional research to determine whether microbiome modulation could treat sleep-wake and circadian disorders.

Fregolente LG, Roth FN, Warncke JD et al. · Sleep medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Beyond air pollution: Green space, water minerals, and genetic predisposition in migraine onset.

This prospective cohort study in 295,881 migraine-free UK Biobank participants (median follow-up 14.47 years) assessed associations between residential green space, coastal proximity, water mineral composition (e.g., magnesium and calcium), and air pollutants (PM2.5, PM10, NO2, NOx) with incident migraine. Higher residential green space was associated with lower migraine risk (HR 0.90), greater coastal distance increased risk (HR 1.30), low water magnesium (HR 1.51) and soft water (HR 1.38) increased risk, and air pollution increased risk by ~13–15%. These findings are clinically relevant because they suggest modifiable environmental exposures and water mineral profiles may contribute to migraine onset risk.

Qiao Y, Cong C, Zhao L et al. · iScience · (2026) · View on PubMed ↗ · Free PDF ↗

A circadian clock gene homolog regulates developmental timing and male mating circuitry in C. elegans.

This study in Caenorhabditis elegans investigated how homologs of circadian clock genes regulate developmental timing and developmental sleep (DTS) and how these processes shape male mating circuitry. The authors found that males show accelerated development with altered DTS patterns and reduced quiescence, but perturbing DTS did not impair functional male mating. The work is significant because it separates developmental sleep from the ability to execute mating behavior, refining how circadian-like timing signals influence neurodevelopmental circuit function.

Nir Halber S, Nir E, Stern S et al. · iScience · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cancer Immunotherapy & Antigen Discovery

Genome-wide profiling of histone modifications and transcription factor binding at single-cell resolution by DeChIC-seq.

DeChIC-seq was developed and evaluated to map protein–DNA interactions at single-cell resolution, focusing on transcription factor (TF) binding and histone modifications using a DNA deaminase-based conversion strategy with a protein A–DddAtox fusion. The method induces localized C-to-U conversions near antibody-bound chromatin to record interactions without immunoprecipitation, enabling genome-wide profiling with improved sensitivity for sparse TF binding. This provides a scalable epigenomics technique for single-cell chromatin interaction mapping that can better resolve TF occupancy and histone states than conventional approaches.

Shi Z, Chen X, Yang Y et al. · Cell research · (2026) · View on PubMed ↗

Beyond the structure-function paradigm: A comprehensive review of intrinsically disordered proteins.

This review examined intrinsically disordered proteins (IDPs) and intrinsically disordered regions (IDRs) and how they operate in signaling, transcription, chromatin organization, and liquid-liquid phase separation (LLPS) rather than adopting stable three-dimensional folds. It concludes that IDPs function as dynamic conformational ensembles enabling high-specificity, low-affinity, multivalent, context-dependent interactions across cellular environments. The synthesis is significant because it reframes structure-function thinking and provides a conceptual foundation for targeting IDP-driven processes in disease and for interpreting LLPS-based cellular organization.

Harake SNA, Btadini S, Qadri AH et al. · Biochemistry and biophysics reports · (2026) · View on PubMed ↗ · Free PDF ↗

TIPs: a deep learning-guided proteogenomic framework to expand the landscape of transposable element-derived antigens with immunopeptidomics.

The study developed TIPs, a deep learning-guided proteogenomic framework integrating de novo sequencing, database refinement, multiple search engines, and stringent FDR control to identify transposable element (TE)-derived HLA-presented antigens using immunopeptidomics across cell lines and cancer types. TIPs detected ~20-fold more TE-derived peptides than conventional approaches and uncovered recurrent tumor-specific TE antigens, including candidates potentially induced by epigenetic therapy. This provides a scalable computational method to expand the TE-derived immunopeptidome and prioritize novel antigen targets for cancer immunotherapy.

Wu Q, Zhou X, Feng Q et al. · Genome biology · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cell & Gene Therapy (CAR-T/Cell Engineering) & Combination Strategies

The development of novel chimeric antigen receptor gamma-delta T cells against multiple myeloma and single-cell RNA sequencing analysis.

This preclinical study developed novel chimeric antigen receptor (CAR) gamma-delta (γδ) T cells targeting B-cell maturation antigen (BCMA) for multiple myeloma and compared them with CAR alpha-beta (αβ) T cells, supported by single-cell RNA sequencing analysis. The key finding was that CAR γδ T cells showed similar activation to CAR αβ T cells but had lower proliferative capacity and less durable cytotoxicity, requiring higher in vivo doses to achieve comparable tumor control. The significance is that it defines performance tradeoffs for off-the-shelf CAR γδ platforms and provides mechanistic insight to guide optimization for BCMA-targeted multiple myeloma therapy.

Hong Y, Zhang C, Wang J et al. · British journal of haematology · (2026) · View on PubMed ↗

Radioligand therapy in combination with CAR T cells overcomes the heterogeneous immunosuppressive prostate tumor microenvironment.

This preprint evaluated combining the FDA-approved radioligand therapy 177Lu-PSMA-617 (Pluvicto; Lu-177 RLT) with PSCA-targeted CAR T cells to treat metastatic castration-resistant prostate cancer (mCRPC) models. The key finding is that the combination can overcome immunosuppressive tumor microenvironment barriers and antigen heterogeneity more effectively than either approach alone in xenograft and mouse syngeneic prostate settings (full results truncated). This is significant because it proposes a strategy to improve durability and efficacy of CAR T therapy in solid tumors where microenvironmental suppression limits responses.

Liu J, Fajnorova I, Ren Y et al. · bioRxiv : the preprint server for biology · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cancer Biomarkers & Liquid Biopsy (ctDNA/Proteomics/Immune Markers)

Plasma Proteomic Changes in GRN and C9orf72 Frontotemporal Dementia.

This study evaluated plasma proteomic changes as blood biomarker candidates in genetic frontotemporal dementia (FTD) by analyzing carriers of pathogenic GRN and C9orf72 mutations and matched non-carriers. Using a multiplex panel of CNS-related proteins, it identified differential plasma protein signatures associated with symptomatic status across GRN and C9orf72 mutation groups. The scientific significance is that these proteomic candidates could support future biomarker development for therapeutic trials aimed at slowing or preventing genetic FTD.

Simrén J, Benedet AL, Di Molfetta G et al. · European journal of neurology · (2026) · View on PubMed ↗ · Free PDF ↗

Baseline peripheral blood immune markers associated with clinical outcomes in patients with advanced breast cancer treated with trastuzumab deruxtecan.

This retrospective single-center study evaluated baseline peripheral blood immune markers (absolute lymphocyte count [ALC], neutrophil-to-lymphocyte ratio [NLR], and platelet-to-lymphocyte ratio) in patients with advanced breast cancer treated with trastuzumab deruxtecan (T-DXd). Baseline immune marker profiles were associated with clinical outcomes after T-DXd, indicating prognostic/predictive value of these readily measurable blood parameters. These findings support using peripheral immune status to stratify advanced breast cancer patients for T-DXd and to guide future biomarker-driven treatment decisions.

Fujimoto A, Ichinose Y, Matsuura K et al. · BMC cancer · (2026) · View on PubMed ↗ · Free PDF ↗

Current Evidence for Circulating Tumor DNA in Sarcoma: Challenges and Opportunities for Clinical Application.

This narrative review evaluated the evidence for using circulating tumor DNA (ctDNA) to detect and monitor sarcoma in multiple sarcoma subtypes, including gastrointestinal stromal tumor, leiomyosarcoma, rhabdomyosarcoma, osteosarcoma, and Ewing sarcoma. It found that while ctDNA detection is feasible, sarcoma’s genomic complexity and heterogeneity have historically limited performance, and the field is rapidly evolving toward clinical application. These findings support ongoing development of ctDNA assays for recurrence risk assessment and treatment monitoring in sarcoma, but highlight the need for subtype- and context-specific validation.

Goodsell KE, Carter JA, Abrams HR et al. · Journal of surgical oncology · (2026) · View on PubMed ↗

Impact of SGLT2 inhibitors in cardiac amyloidosis: A systematic review and meta-analysis.

This systematic review and meta-analysis evaluated the impact of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on outcomes in patients with cardiac amyloidosis (AL and ATTR) using seven observational studies (N=13,303). The key finding was that SGLT2i use was associated with differences in clinical outcomes such as mortality, heart failure exacerbations, estimated GFR (eGFR), and NT-proBNP compared with matched controls. Scientifically, it clarifies whether SGLT2i benefits extend to cardiac amyloidosis beyond general heart failure populations, while also highlighting the need for higher-quality evidence given the observational design.

Nandyal S, Vij A, Varma R et al. · American heart journal plus : cardiology research and practice · (2026) · View on PubMed ↗ · Free PDF ↗

ESR1 and PIK3CA circulating tumor DNA (ctDNA) mutation status as predictive biomarkers beyond variant allele fraction (VAF) in metastatic breast cancer.

This study assessed whether circulating tumor DNA (ctDNA) mutation status for ESR1 and PIK3CA in metastatic breast cancer predicts outcomes beyond variant allele fraction (VAF). The key finding was that interpreting ESR1/PIK3CA alterations requires considering VAF limitations and that mutation status can provide additional predictive information independent of VAF. Clinically, this supports more robust ctDNA biomarker interpretation for hormone receptor–positive/HER2-negative metastatic breast cancer when selecting actionable alterations.

Fusco N, Malapelle U · The journal of liquid biopsy · (2026) · View on PubMed ↗ · Free PDF ↗

CD8+CD38+ T cells identify functional high-risk multiple myeloma after autologous transplant: BMT CTN 0702 correlates.

This study analyzed immune correlates of functionally high-risk multiple myeloma (MM) after autologous stem cell transplantation (ASCT) using immunohistochemistry (IHC) and high-dimensional flow cytometry in patients from BMT CTN 0702. It identified CD8+CD38+ T cells as markers of functional high-risk MM at day 100 after ASCT, distinguishing early-relapse (within 24 months) patients with worse outcomes. The significance is that these T-cell phenotypes could enable earlier immune-based risk stratification to guide post-transplant management in MM.

Mehanna N, Derkach A, Gasmi B et al. · Blood neoplasia · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cancer Therapeutics & Treatment Sequencing (Trials/Real-world Evidence)

The novel hypomethylating agent NTX-301 reprograms epigenetic and Hippo signaling pathways and exhibits pre-clinical activity in venetoclax-resistant and TP53-mutant AML.

This pre-clinical study evaluated the next-generation hypomethylating agent NTX-301 in venetoclax-resistant and TP53-mutant acute myeloid leukemia (AML) models, using flow cytometry viability assays, Western blot, reverse-phase protein arrays, RNA-seq, CyTOF single-cell mass cytometry, and methylation profiling. NTX-301 showed superior anti-leukemic efficacy versus 5-azacytidine and was linked to reprogramming of epigenetic programs and Hippo signaling pathways in these therapy-resistant settings. These findings support NTX-301 as a mechanistically targeted HMA strategy for high-risk AML patients, particularly those with TP53 mutations and venetoclax resistance.

Carter BZ, Mak PY, Satpati S et al. · Clinical cancer research : an official journal of the American Association for Cancer Research · (2026) · View on PubMed ↗

Benefit of adjuvant chemotherapy for resected pancreatic cancer following neoadjuvant FOLFIRINOX or Gemcitabine-Nab-paclitaxel: a multinational analysis.

This multinational retrospective cohort analysis studied whether adjuvant chemotherapy improves overall survival after curative-intent resection for resected borderline resectable pancreatic cancer (BRPC) or locally advanced pancreatic cancer (LAPC), stratified by neoadjuvant and adjuvant regimens. The study specifically assessed outcomes following neoadjuvant FOLFIRINOX or gemcitabine–nab-paclitaxel, addressing prior limitations from pooling heterogeneous stages and regimens. Clinically, regimen-stratified evidence can better guide decisions about using adjuvant chemotherapy after NAT and resection in PDAC.

Lopez-Lopez V, Hasse T, Houben P et al. · Journal of the National Cancer Institute · (2026) · View on PubMed ↗

Genome-wide CRISPR-Cas9-based screening revealed the role of ubiquitin ligase TRIM25 in ribosome degradation via ribophagy.

This cell-based mechanistic study used genome-wide CRISPR-Cas9 screening with a fluorescent ribophagy reporter (RPL29-mCherry/GFP) to identify regulators of ribosome degradation via ribophagy. The screen revealed the ubiquitin ligase TRIM25 as a key factor in ribophagy-mediated ribosome degradation, linking TRIM25 to ribosome quality control pathways. These findings are significant for understanding ribophagy regulation and may inform therapeutic strategies for ribosomopathies caused by impaired ribosome turnover.

Golubeva J, Mikhailov A, Shepelev N et al. · Autophagy · (2026) · View on PubMed ↗

METTL5-mediated rRNA modification controls prostate cancer progression through the IRF7/DNA2 axis and mitophagy regulation.

This mechanistic study examined the role of the rRNA m6A methyltransferase METTL5 in prostate cancer progression, including METTL5-dependent N6-methyladenosine (m6A) modification at A1832 of 18S rRNA and downstream control of the IRF7/DNA2 axis and mitophagy. METTL5 was upregulated during progression and promoted tumor growth by enhancing translation via 18S rRNA m6A at A1832, with integrative transcriptomic/proteomic analyses linking METTL5 activity to mitophagy regulation. Clinically, METTL5-dependent rRNA modification and the IRF7/DNA2/mitophagy pathway may represent actionable targets to slow prostate cancer progression.

Yang R, Ge Q, Wu F et al. · Oncogene · (2026) · View on PubMed ↗

Tumor heterogeneity: development, mechanisms, and therapeutic implications.

This review article synthesized current knowledge on tumor heterogeneity, focusing on its development from genomic instability, clonal evolution, and cancer stem cell plasticity, and its amplification by tumor microenvironment interactions. It highlights how single-cell multi-omics, spatial transcriptomics, and liquid biopsy now enable multidimensional characterization of heterogeneity that underlies therapeutic resistance and relapse. The review frames these advances as essential for designing more effective, heterogeneity-aware cancer therapies.

Zhang J, Li H, Ru S et al. · Signal transduction and targeted therapy · (2026) · View on PubMed ↗ · Free PDF ↗

Treatment inequity among older adults with newly diagnosed acute myeloid leukemia ineligible for intensive therapy.

This retrospective cohort study used Medicare fee-for-service claims to examine treatment inequity among older adults with newly diagnosed acute myeloid leukemia (AML) who were ineligible for intensive therapy (≥75 years and/or unfit), totaling 12,154 patients. It found that only 5,647 received AML-directed therapy, and the analysis identified demographic and other factors associated with receipt of venetoclax plus hypomethylating agents (VEN+HMA) in real-world practice. The significance is that it quantifies disparities in access to the current standard regimen for unfit older AML patients and highlights targets for improving equitable treatment uptake.

Mina A, Xu Y, Kapustyan TA et al. · Leukemia & lymphoma · (2026) · View on PubMed ↗

Effectiveness and safety of enfortumab vedotin and pembrolizumab in a real-world patient population with urothelial carcinoma: results from a multi-institutional cohort (GUARDIANS).

This multi-institutional retrospective cohort study (GUARDIANS) evaluated real-world effectiveness and safety of enfortumab vedotin plus pembrolizumab (EVP) in patients with metastatic or locally advanced urothelial carcinoma treated across 25 German hospitals. The key finding was that outcomes and adverse events in routine practice were assessed against the expectations from the pivotal EV-302/KEYNOTE-A39 trial despite frequent real-world unfavorable baseline characteristics. Clinically, the study informs whether EVP performs similarly outside trial populations and supports decision-making for first-line treatment in broader urothelial cancer care.

Zschäbitz S, Bhatti I, Casuscelli J et al. · Cancer immunology, immunotherapy : CII · (2026) · View on PubMed ↗ · Free PDF ↗

Scaled Multidimensional Assays of Variant Effect Identify Sequence-Function Relationships in Hypertrophic Cardiomyopathy.

This study developed scalable multidimensional functional assays to map sequence-to-function relationships for variants causing hypertrophic cardiomyopathy (HCM), focusing on the MYBPC3 gene encoding cardiac myosin-binding protein C (cMyBP-C). The key finding was that the scaled variant effect approach can quantify functional impacts of MYBPC3 variants, helping resolve variants of uncertain significance by linking genotype to disease-relevant cellular phenotypes. Clinically, this supports more accurate genetic interpretation and improved risk stratification and family counseling in HCM.

Yamamoto Y, Chua K, Staudt D et al. · Circulation · (2026) · View on PubMed ↗

Postoperative gabapentinoid use is associated with improved survival in glioblastoma: A nationwide population-based study.

This nationwide Turkish registry study examined whether postoperative gabapentinoid use is associated with overall survival in adult patients with pathology-confirmed glioblastoma who underwent surgery between 2016 and 2024. Using stabilized inverse probability of treatment weighting (sIPTW) to adjust for confounding, postoperative gabapentinoid exposure was associated with improved overall survival compared with no use. The results support a potential survival-modifying role of gabapentinoids in glioblastoma and justify further prospective validation.

Hanalioglu S, Cekic E, Gok E et al. · Neuro-oncology advances · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cardio-Oncology & Cardiovascular Toxicity

Transforming Pulmonary Arterial Hypertension: Key Milestones and Future Perspectives.

This review article synthesized key milestones and future directions in pulmonary arterial hypertension (PAH), a progressive precapillary pulmonary vascular disease affecting patients through endothelial dysfunction, smooth muscle hyperproliferation, inflammation, and dysregulated signaling pathways. It summarizes how advances in understanding PAH pathobiology, epidemiology, diagnosis, and treatments have improved patient outcomes over the past four decades. The review is clinically significant for guiding next-step research and informing evolving therapeutic strategies targeting prostacyclin, nitric oxide, endothelin-1, and bone morphogenetic/TGF-β pathways.

Humbert M, Zeder K, Kovacs G et al. · Circulation · (2026) · View on PubMed ↗

Circadian genotypes in PER3 and time of prostate cancer radiotherapy interact to affect risk of late side-effects.

This study examined whether circadian genotypes in PER3 and the time of day of prostate cancer external beam radiotherapy interact to influence the risk of late radiotherapy side-effects in the multinational prospective observational REQUITE cohort (n=1760). It tested genotype-by-treatment-time effects on toxicity outcomes over a 2-year follow-up period. If confirmed, the results support genetically guided chronomodulation as a strategy to reduce late adverse effects while maintaining radiotherapy efficacy.

Webb AJ, Harper E, Rattay T et al. · Clinical cancer research : an official journal of the American Association for Cancer Research · (2026) · View on PubMed ↗ · Free PDF ↗

Androgen Deprivation Therapy and Cardiovascular Health: Challenges and Opportunities in Prostate Cancer Care.

This narrative review assessed cardiovascular (CV) toxicity associated with androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPIs) in men with advanced prostate cancer. It concluded that ADT/ARPI improve prostate cancer outcomes but increase risk of cardiovascular disease, making CV risk assessment and prevention a key competing determinant of morbidity and mortality. The article’s clinical significance is to guide practical strategies for CV risk stratification and mitigation while using ADT/ARPIs.

Fernández Alonso S, López Campos F, Büchser D et al. · Archivos espanoles de urologia · (2026) · View on PubMed ↗

Atherosclerotic Cardiovascular Disease and Cancer.

This review examined how shared immune mechanisms link atherosclerotic cardiovascular disease (ASCVD) and cancer across exposures such as smoking, obesity, diabetes, dyslipidemia, aging, and clonal hematopoiesis of indeterminate potential (CHIP). It highlights a forward cardio-oncology axis in which cancer therapies (chemotherapy, radiation, and immune checkpoint inhibitors) can induce cardiovascular injury through coordinated reprogramming of myeloid and lymphoid immune compartments. The synthesis supports targeting immune pathways that drive both ASCVD and treatment-related cardiotoxicity to improve cardio-oncology outcomes.

Amend A, Horstmann H, Lavine KJ et al. · Immunological reviews · (2026) · View on PubMed ↗ · Free PDF ↗

---

Metabolic Disease & Cardio-Renal-Metabolic Pharmacotherapy

Physical activity for the management of obesity in children up to the age of 9 years.

This Cochrane systematic review synthesized evidence on physical activity interventions for managing obesity in children up to age 9 years, focusing on benefits and harms rather than prevention. It searched multiple databases and trial registries (2012 to 2 June 2023, updated 4 December 2025) to evaluate outcomes relevant to obesity management. The review is clinically significant for informing pediatric obesity care by clarifying whether physical activity improves weight-related outcomes and what risks, if any, are associated with these interventions.

Loaiza-Betancur AF, Iglesias Gonzalez LE, Chavez Guapo N et al. · The Cochrane database of systematic reviews · (2026) · View on PubMed ↗

Disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis after failure of biologic or targeted synthetic therapy: a systematic review and network meta-analysis.

This study investigated how nutrient-sensing Rag GTPases and mTORC1 regulate intestinal stem cell (ISC) activity in response to dietary availability using Drosophila intestinal epithelial cells. It found that inhibiting Rag GTPases or inactivating mTORC1 in enterocytes activates the Upd3–JAK-STAT pathway (via Mitf for Rag inhibition), non-cell autonomously increasing ISC proliferation and differentiation. These mechanistic insights are significant for understanding how conserved nutrient-signaling pathways control stem cell behavior and tissue homeostasis.

Thomas J, Kamso MM, Whittle SL et al. · The Cochrane database of systematic reviews · (2026) · View on PubMed ↗

Newer and novel antidiabetic drug classes across the cardiovascular-kidney-metabolic continuum.

This review article surveyed newer and emerging antidiabetic drug classes across the cardiovascular–kidney–metabolic (CKM) continuum, emphasizing therapies that affect outcomes beyond glucose lowering. It highlights classes such as SGLT2 inhibitors and GLP-1 receptor agonists (GLP-1RAs), and discusses dual or combination approaches aimed at cardiorenal-metabolic risk. The review is clinically significant because it frames how modern diabetes pharmacotherapy can target interconnected pathways driving cardiovascular disease and chronic kidney disease.

Stefanakis K, Karakasis P, Vasdeki D et al. · Endocrine reviews · (2026) · View on PubMed ↗

Sarcopenic Obesity and Risk of Incident Type 2 Diabetes: A Prospective Cohort Study and Landmark Analysis From the UK Biobank.

This prospective cohort and landmark analysis studied whether sarcopenic obesity (SO) predicts incident type 2 diabetes (T2D) beyond obesity or sarcopenia alone in 479,607 diabetes-free UK Biobank participants. Over a median 14.2-year follow-up, SO conferred the highest T2D risk (hazard ratio 3.54), exceeding obesity alone and sarcopenia alone, with additional analyses of body-composition phenotype transitions. Clinically, SO may identify individuals at substantially elevated T2D risk who could benefit from earlier prevention strategies targeting both excess fat and low muscle function.

Guan Z, Stephan BCM, Siervo M · Diabetes care · (2026) · View on PubMed ↗

Ubiquitination of ACSL4 by Parkin Suppresses Ferroptosis and Rescues Glucocorticoid-Induced Bone Loss.

This mechanistic study investigated how Parkin regulates ACSL4-mediated ferroptosis in glucocorticoid-induced osteoporosis (GIOP) using dexamethasone-treated bone marrow mesenchymal stem cells (BMSCs) and a GIOP mouse model. Glucocorticoids induced ferroptosis in BMSCs, Parkin was downregulated in GIOP, and Parkin knockdown worsened lipid peroxidation, iron accumulation, and mitochondrial dysfunction while impairing osteogenesis and promoting adipogenesis; ubiquitination of ACSL4 by Parkin suppressed ferroptosis and rescued bone loss. These results support a Parkin–ACSL4 axis as a potential therapeutic target, including a bone-targeted mRNA approach, to prevent or treat GIOP.

Han LJ, Miao JS, Shi YF et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗ · Free PDF ↗

Plasma proteomic profiling deciphers molecular dynamics linking insulin resistance to multiple chronic diseases and mortality.

This UK Biobank study used plasma proteomic profiling (2,920 proteins) in 19,556 individuals to derive insulin resistance (IR)-related protein signatures using elastic net modeling and then tested associations with multiple chronic diseases and mortality using Cox proportional hazards models. It identified IR-associated proteomic signature scores that longitudinally related to health outcomes, and performed mediation analyses to evaluate whether specific proteins help explain these associations (details truncated). The approach provides candidate protein biomarkers and mechanistic links connecting insulin resistance to broad disease risk and death.

Zhou ZL, Zhou LG, Qu CH et al. · Cardiovascular diabetology · (2026) · View on PubMed ↗ · Free PDF ↗

Cardiovascular outcomes of empagliflozin-GLP-1RA combination therapy in type 2 diabetes: EMPRISE study.

This EMPRISE cohort study emulated two comparative effectiveness trials using US claims databases (Medicare and Optum Clinformatics/MarketScan, 2013–2022) to evaluate cardiovascular outcomes in adults with type 2 diabetes initiating empagliflozin and then augmenting with either a GLP-1 receptor agonist (GLP-1RA) or a DPP-4 inhibitor (DPP-4i). It compared outcomes between empagliflozin-first strategies followed by GLP-1RA versus DPP-4i augmentation (full results truncated in the abstract). The study aims to provide real-world evidence on whether combining empagliflozin with GLP-1RA improves cardiovascular outcomes beyond alternative add-on therapy in routine care.

Htoo PT, Cho H, Paik JM et al. · Cardiovascular diabetology · (2026) · View on PubMed ↗ · Free PDF ↗

From Gut to Fat: Intestinal Epithelial Exosomes Target PDGFRα+ Progenitors to Promote Lipogenesis and Counteract Subcutaneous Adipose Tissue Atrophy in Aging.

This study investigated how small intestinal epithelium-derived exosomes (SI-Exos) regulate age-related subcutaneous adipose tissue (SAT) atrophy by targeting PDGFRα+ progenitors, using young SI-Exos administration in aged mice. Young SI-Exos increased lipid droplet formation, reversed SAT atrophy, and reduced inflammation in visceral adipose tissue, with effects mediated by age-altered miRNA cargo. These gut-to-fat exosome findings suggest a potential therapeutic route to counteract age-associated adipose wasting by modulating exosomal miRNAs and PDGFRα+ progenitor activity.

Huang T, Huang Y, Zhou Y et al. · Aging cell · (2026) · View on PubMed ↗ · Free PDF ↗

Glucagon-like peptide-1 receptor agonists and cardiovascular outcomes in dialysis patients with type 2 diabetes: a real-world propensity score-matched study.

This retrospective propensity score-matched real-world study used the TriNetX US Collaborative Network (2013–2022) to compare new users of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) versus dipeptidyl peptidase-4 inhibitors (DPP-4i) in 1,688 matched pairs of patients with type 2 diabetes on dialysis. The study evaluated major adverse cardiovascular events (MACE) and multiple secondary outcomes including all-cause mortality and heart failure, finding GLP-1 RA outcomes that were assessed against DPP-4i in this high-risk population (full effect estimates truncated in the abstract). This is clinically significant because it addresses an evidence gap for GLP-1 RA cardiovascular benefit in dialysis patients with T2DM.

Chen JJ, Tsai MH, Ho WY et al. · Clinical kidney journal · (2026) · View on PubMed ↗ · Free PDF ↗

Understanding reasons for initiation and experience with tirzepatide among individuals with obesity or overweight: Results from the PERCEPTIONS survey.

The PERCEPTIONS survey studied real-world reasons for initiation and early experiences with tirzepatide among US adults with obesity (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2 with ≥1 obesity-related complication) without type 2 diabetes mellitus. Key findings (from baseline survey data) characterize how participants decided to start tirzepatide and their initial treatment experience in an obesity-medication–eligible population. These real-world insights complement SURMOUNT trial efficacy by informing patient-facing adoption and expectations for tirzepatide in routine clinical care.

Gibble TH, Makin H, Gerber C et al. · Obesity pillars · (2026) · View on PubMed ↗ · Free PDF ↗

Primary Cilia as Integrative Hubs of Metabolic Signaling in Type 2 Diabetes: Inter-Organ Evidence From Central, Peripheral, and Pancreatic Islet Tissues.

This review integrated evidence on primary cilia as hubs of metabolic signaling in type 2 diabetes (T2D) across central nervous system, peripheral tissues, and pancreatic islets. It highlights how primary cilia regulate pathways including Hedgehog (Hh), Wnt, GPCR signaling, and mTOR, and it summarizes cilia-linked mechanisms involving metabolic dysregulation. The synthesis is significant because it frames primary cilia as potential therapeutic targets and provides a methodological roadmap for studying cilia-driven metabolic control in T2D.

Liang M, Wen C, Deng L et al. · Journal of cellular physiology · (2026) · View on PubMed ↗

---

Liver Disease (MASLD/MASH/Cirrhosis) & Hepatic Mechanisms

Drug Development for MASH-Related Compensated Cirrhosis: Past, Present and Future.

This review studied the landscape of drug development for metabolic dysfunction-associated steatohepatitis (MASH)-related compensated cirrhosis, a condition with no approved therapy to date. It found that multiple drug classes originally developed for non-cirrhotic MASH—such as fibroblast growth factor 21 analogues, GLP-1 receptor/glucagon dual agonists, thyroid hormone receptor-β agonists, and other emerging agents—are being advanced into compensated cirrhosis trials despite added challenges from persistent inflammation and portal hypertension. The significance is to map past and current therapeutic directions and identify future opportunities for effective treatments in this high-need hepatology population.

Zeng RQ, Shao YX, Lin RT et al. · Liver international : official journal of the International Association for the Study of the Liver · (2026) · View on PubMed ↗

Macrophage Notch1 drives hepatocyte ferroptosis via the exosomal miR-142a-3p/TIPE2 axis to promote MASH progression.

This study examined how macrophage Notch1 regulates hepatocyte ferroptosis to drive metabolic dysfunction-associated steatohepatitis (MASH) progression via an exosomal miR-142a-3p/TIPE2 axis in patients and mouse models. Macrophage-specific Notch1 knockout (Notch1M-KO) mice showed reduced liver injury, lipid accumulation, inflammation, and collagen deposition, alongside decreased hepatocyte ferroptosis markers including lower Fe2+ and pro-ferroptotic gene expression (abstract truncated). The work links a defined immune–hepatocyte signaling pathway (Notch1 → exosomal miR-142a-3p → TIPE2) to ferroptosis in MASH, suggesting targets for mechanistically guided therapy.

Dong X, Zhang M, Huang X et al. · Cell & bioscience · (2026) · View on PubMed ↗ · Free PDF ↗

Sex- and menopause-specific inverse associations between metabolic dysfunction-associated steatotic liver disease and serum lipoprotein(a) concentrations: evidence from SHIP and UK Biobank.

This cohort study assessed sex- and menopause-specific associations between metabolic dysfunction-associated steatotic liver disease (MASLD), liver fat content (LFC), and transaminases with serum lipoprotein(a) [Lp(a)] concentrations using SHIP-START-0 (n=3,825) and UK Biobank (n=28,504). It reports inverse associations stratified by sex and menopausal status, indicating that the MASLD–Lp(a) relationship differs across these biological subgroups (abstract truncated). These findings may refine cardiovascular risk stratification by accounting for sex and menopausal status when evaluating MASLD-related Lp(a) biology.

de Souza JG, Ittermann T, Werner N et al. · Cardiovascular diabetology · (2026) · View on PubMed ↗ · Free PDF ↗

Thyroid-Liver Axis: Mechanistic Insights and Clinical Implications.

This narrative review examined the bidirectional thyroid–liver axis, focusing on how thyroid hormones regulate hepatic metabolism and how the liver controls thyroid hormone transport, activation, metabolism, and clearance. The key finding was that thyroid dysfunction is mechanistically linked to metabolic dysfunction–associated steatotic liver disease (MASLD), fibrosis progression, and adverse metabolic outcomes. Scientifically and clinically, the review consolidates current mechanistic and therapeutic implications to guide evaluation and management of patients with coexisting thyroid and liver disorders.

Parveen N, Chittawar S, Khandelwal D et al. · Cureus · (2026) · View on PubMed ↗ · Free PDF ↗

---

Kidney Disease & Renal Therapies (including CKD-MBD/AKI/Nephrology)

Mineral and Bone Disease in CKD and Kidney Transplantation: Controversies, Gaps, and a Path Forward.

This review studied chronic kidney disease–related mineral and bone disorder (CKD-MBD) in patients with CKD and kidney transplant recipients, focusing on updated conceptual frameworks beyond secondary hyperparathyroidism. It found that CKD-MBD comprises two overlapping syndromes—CKD-associated osteoporosis (with increased fracture risk and microarchitectural deterioration) and CKD-associated cardiovascular disease (including medial vascular calcification and cardiac structural/vascular abnormalities). The significance is that recognizing these distinct but linked syndromes can improve diagnosis, risk prediction, and targeted prevention strategies in CKD and transplant care.

Kanbay M, Aktas O, Copur S et al. · Kidney international reports · (2026) · View on PubMed ↗ · Free PDF ↗

Osteoporosis medication exposure patterns and MRONJ occurrence in patients receiving romosozumab: a retrospective observational study.

This retrospective observational study used electronic medical records and prescription/administration data to characterize invasive dental procedures and medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients receiving romosozumab. MRONJ occurrence was analyzed according to the timing of romosozumab exposure relative to tooth extraction and/or implant placement (before, after, or both before and after). The results can inform dental management and risk mitigation strategies for romosozumab-treated patients undergoing invasive oral procedures.

Kim J, Choi EJ, Kim JY et al. · Clinical oral investigations · (2026) · View on PubMed ↗

Acetaminophen Overdose in an Extremely Low-Birth-Weight Premature Infant: A Case Report and Review of the Literature.

This case report studied acetaminophen (paracetamol, APAP) overdose in an extremely low-birth-weight premature infant, emphasizing developmental differences in drug metabolism. The key finding was that the infant’s immature glucuronidation and cytochrome P450 oxidative pathways, reliance on sulfation, and relatively preserved glutathione stores complicate toxicity risk assessment and interpretation of conventional pediatric/adult dosing assumptions. The report is clinically significant because it highlights the need for heightened vigilance and tailored management strategies for APAP exposure in extremely premature neonates.

Pham A, Ohler K, Gimbar RP et al. · Cureus · (2026) · View on PubMed ↗ · Free PDF ↗

Advances and perspectives of functional nanomaterials in scavenging reactive oxygen species for acute kidney injury.

This article reviewed functional nanomaterials engineered to scavenge reactive oxygen species (ROS) in the context of acute kidney injury (AKI), where oxidative stress intersects with inflammation, ferroptosis, and mitochondrial dysfunction. It highlights that nanotechnology approaches aim to overcome limitations of conventional ROS-targeting therapies such as low bioavailability, poor renal targeting, and systemic toxicity through rational design and surface modification. The review is significant because it maps current strategies and future directions for nanomaterial-based ROS control as a potential therapeutic route in AKI.

Luo L, Lin S, Wang L et al. · Bioactive materials · (2026) · View on PubMed ↗ · Free PDF ↗

The Efficacy and Safety of Telitacicept versus the Recommended Regimens in IgA Nephropathy: A Single-Center Experience.

In a single-center retrospective cohort of 101 biopsy-confirmed IgA nephropathy patients, investigators compared glucocorticoids (GC), telitacicept, and nefecon to evaluate efficacy and safety relative to the 2025 KDIGO-recommended regimens. The study found differences in clinical outcomes across treatment groups, with telitacicept demonstrating comparative efficacy and an acceptable safety profile in this real-world setting. These data help clinicians position telitacicept among emerging IgAN therapies when choosing between GC-based and guideline-aligned options.

Li X, Zhang Y, Xu C et al. · Drug design, development and therapy · (2026) · View on PubMed ↗ · Free PDF ↗

A simple suspension culture method for generating human iPSC-derived liver organoids.

This methods paper developed a simple, scalable suspension culture approach to generate human induced pluripotent stem cell (iPSC)-derived liver organoids. The key advance is a suspension-culture workflow that avoids reliance on exogenous extracellular matrix scaffolds or specialized equipment, aiming to improve standardization and scalability while maintaining liver-relevant functions. This enables broader, more reproducible 3D liver models for toxicity testing requiring metabolic competence.

Morozumi R, Kinoshita M, Takahashi R et al. · Biology methods & protocols · (2026) · View on PubMed ↗ · Free PDF ↗

---

Autoimmunity, Inflammation & Immune Signaling (non-cancer)

Interleukin 6 Receptor Blockade for Relapse Prevention in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

This international multicenter retrospective cohort study evaluated interleukin-6 receptor blockade (IL-6RB) as relapse-preventive therapy in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and compared relapse frequency with intravenous immunoglobulin (IVIG). The key analysis assessed whether IL-6RB reduces relapses and how its relapse rate compares to IVIG in patients treated across 2015–2025. The findings are important because MOGAD has limited proven relapse-preventive options and IL-6RB could offer a safer or more practical alternative if efficacy is demonstrated.

Vilaseca A, Bilodeau PA, Gakis G et al. · JAMA neurology · (2026) · View on PubMed ↗

Rag GTPases and mTORC1 regulate intestinal stem cell activity in response to nutrient availability.

This living systematic review and network meta-analysis evaluated disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis in adults after failure of biologic or targeted synthetic DMARD therapy. It compared benefits and harms across alternative DMARD options using an evidence network built from trials identified through searches up to 28 November 2025. The results are important for evidence-based treatment sequencing by clarifying comparative effectiveness and safety when patients do not respond to initial b/ts DMARDs.

Fan W, Ge C, Niu C et al. · The Journal of cell biology · (2026) · View on PubMed ↗

Navigating sexual health, fertility, and adult wellness in individuals with Duchenne muscular dystrophy: Current standards of care and future directions.

This narrative review assessed current standards of care and future research directions for sexual health, fertility, and adult wellness in individuals with Duchenne muscular dystrophy (DMD). The authors highlight that while clinical guidance emphasizes addressing these psychosocial domains, robust evidence on how DMD specifically affects sexual and reproductive health remains limited. The review’s significance is to define care gaps and prioritize research to improve counseling and management for adolescents and adults living with DMD.

Nasomyont N, Appel A, Apkon S et al. · Journal of neuromuscular diseases · (2026) · View on PubMed ↗ · Free PDF ↗

Successful dose reduction of dupilumab in pediatric patients with atopic dermatitis in daily practice: results from the BioDay registry.

This real-world registry study (BioDay) evaluated successful dose reduction of dupilumab in pediatric patients with atopic dermatitis (≤16 years) treated in daily practice. Among 278 children, 126 with controlled disease were eligible for dose reduction, and outcomes included the proportion achieving successful reduction and changes in Eczema Area and Severity Index (EASI) and pruritus numeric rating scale (NRS) over time. The findings are clinically relevant for informing individualized dupilumab dosing strategies that maintain disease control while potentially reducing treatment burden in pediatric AD.

Vroman F, Bacoş-Cosma OI, de Krosse LC et al. · Expert opinion on biological therapy · (2026) · View on PubMed ↗

Systematic review- hormone replacement therapy in postmenopausal women with medical co-morbidities.

This systematic review synthesized evidence on hormone replacement therapy (HRT) in peri- and postmenopausal women with medical comorbidities. It searched PubMed, Embase, Cochrane Central, and Web of Science through 31 August 2025 and aimed to summarize disease-specific safety and efficacy outcomes across study designs. The significance is to support more condition-specific clinical decision-making for HRT in women with chronic illnesses by clarifying where evidence is strong versus uncertain.

Sachdeva G, Kumar G, Kumar B · Post reproductive health · (2026) · View on PubMed ↗

Autoimmune diseases in the era of COVID-19: emerging mechanisms, clinical implications, vaccine considerations, and future directions.

This review examined the bidirectional relationship between SARS-CoV-2 infection and autoimmune diseases in patients with systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, and Guillain-Barré syndrome. It found that autoimmune patients have increased risk of severe COVID-19 due to immune dysregulation and immunosuppressive therapies, while COVID-19 can trigger or worsen autoimmune disease activity. The synthesis highlights implications for clinical management and vaccine considerations during the COVID-19 era, emphasizing the need for future research on mechanisms and outcomes across autoimmune conditions.

Kong J, Hong S, Oh J et al. · The Korean journal of internal medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Effect of once-daily ICS/LAMA/LABA triple therapy versus ICS/LABA on respiratory symptoms (E-RS: Asthma): Analysis of the phase IIIA CAPTAIN trial.

This phase IIIA randomized CAPTAIN trial analysis studied adults with uncontrolled moderate-to-severe asthma who were treated with once-daily inhaled triple therapy (fluticasone furoate/vilanterol plus umeclidinium) versus inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) alone (FF/VI). The key finding was the effect of adding the long-acting muscarinic antagonist umeclidinium (UMEC) to FF/VI on respiratory symptoms over the 24- to 52-week study period. Clinically, the results inform whether UMEC-based triple therapy provides symptom benefits beyond lung-function improvements in this asthma population.

Pizzichini E, Brusselle G, Crawford J et al. · The journal of allergy and clinical immunology. Global · (2026) · View on PubMed ↗ · Free PDF ↗

Rapidly Progressive Triple M Overlap Syndrome After Immune Checkpoint Inhibitor Therapy.

This case report studied an 85-year-old man with metastatic renal cell carcinoma who developed rapidly progressive triple M overlap syndrome after immune checkpoint inhibitor therapy with pembrolizumab plus lenvatinib. The key finding was that he developed the triad of ICI-mediated myositis, myocarditis, and myasthenia gravis within weeks of starting treatment, consistent with a rare and often fatal complication. The clinical significance is heightened awareness and early recognition of triple M overlap syndrome in patients receiving ICI-based regimens to enable prompt management.

Garrett S, Ansari A, Siddada S et al. · Cureus · (2026) · View on PubMed ↗ · Free PDF ↗

Nutrition and Exercise in Critical Illness (NEXIS) trial: randomized trial of combined in-bed cycling and intravenous amino acid plus usual care.

This multicenter phase 2 randomized trial studied critically ill ICU patients with acute respiratory failure who received early in-bed cycling plus intravenous amino acids versus usual care alone. The key finding (as assessed by blinded measurement) was the effect on physical functioning, with 6-minute walk distance at hospital discharge as the primary outcome. The clinical significance is whether combining early mobilization with targeted protein delivery can improve functional recovery in immobile, nutritionally limited ICU patients.

Needham DM, Files DC, Hough CL et al. · American journal of respiratory and critical care medicine · (2026) · View on PubMed ↗

Dual orexin receptor antagonists for preventing delirium in hospitalized older adults: protocol for a randomized-trial systematic review and meta-analysis.

This protocol describes a randomized-trial systematic review and meta-analysis to test whether dual orexin receptor antagonists (DORAs)—suvorexant, lemborexant, and daridorexant—prevent delirium in hospitalized older adults. It will synthesize evidence from randomized trials assessing delirium outcomes in older inpatients, using the DORA mechanism of antagonizing orexin-mediated wakefulness rather than direct GABAergic sedation. The study is intended to clarify the clinical applicability of DORA evidence for delirium prevention in real-world hospitalized geriatric populations.

He S, Zeng J, Zhang Y et al. · Systematic reviews · (2026) · View on PubMed ↗ · Free PDF ↗

The 2026 British Society of Gastroenterology guidelines on the diagnosis and management of adult coeliac disease.

This guideline update from the British Society of Gastroenterology reviewed evidence-based standards for diagnosing and managing adult coeliac disease (CD) across multiple international contributing regions. It emphasizes updated diagnostic and treatment approaches for adult patients with CD based on recent advances. Clinically, the guideline aims to standardize care and improve outcomes for adults with coeliac disease.

Penny HA, Shiha MG, Raju SA et al. · Gut · (2026) · View on PubMed ↗

Meta-Analysis: Chronic Gastrointestinal Symptoms and Comorbidities in Hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorders.

This systematic review and meta-analysis assessed the prevalence of chronic gastrointestinal (GI) symptoms and related comorbidities in patients with hypermobile Ehlers-Danlos syndrome (hEDS) and hypermobility spectrum disorders (HSD), pooling data from 19 studies (17,455 participants). It found elevated rates of chronic GI symptoms and gut-brain interaction disorders along with extraintestinal comorbidities compared with what is typically expected in the general population. The significance is that it strengthens evidence for a high burden of GI and comorbid conditions in hEDS/HSD, supporting more proactive screening and integrated management.

Kulin D, Holtmann G, Fairlie T et al. · Alimentary pharmacology & therapeutics · (2026) · View on PubMed ↗ · Free PDF ↗

Comparison of the Efficacy of Different Doses of Glucocorticoid Nasal Spray Combined with Loratadine in the Treatment of Rhinitis in Children: A Randomized Clinical Trial.

This randomized clinical trial studied 150 children with rhinitis comparing low-, medium-, and high-dose glucocorticoid nasal spray combined with loratadine. The key finding was that different glucocorticoid doses (all combined with loratadine) produced differing efficacy and immunologic/inflammatory biomarker responses across the three groups. Clinically, the trial supports dose optimization of intranasal glucocorticoids plus loratadine to improve pediatric rhinitis outcomes while monitoring inflammatory effects.

Wang H, Ren Z · Iranian journal of allergy, asthma, and immunology · (2026) · View on PubMed ↗

Enhanced EBNA2-dependent activity in EBV-transformed B cells from patients with multiple sclerosis.

This study investigated Epstein–Barr virus (EBV) effects on gene expression, chromatin accessibility, and transcription factor binding in EBV-transformed B cells derived from patients with multiple sclerosis versus healthy controls, using RNA-seq and ATAC-seq. EBV-transformed B cells showed extensive MS-dependent differences in gene expression and chromatin accessibility, whereas primary B cells did not. These findings strengthen the mechanistic link between EBV-driven B-cell programs and MS risk and highlight EBNA2-dependent regulatory activity as a candidate pathway.

Granitto M, Kim E, Forney C et al. · medRxiv : the preprint server for health sciences · (2026) · View on PubMed ↗ · Free PDF ↗

Successful salvage treatment with baricitinib for macrophage activation syndrome complicating adult-onset Still’s disease during interleukin-6 inhibition: a case report and literature review.

This case report and literature review described a 49-year-old woman with adult-onset Still’s disease who developed fulminant macrophage activation syndrome while receiving high-dose glucocorticoids, tacrolimus, and the interleukin-6 receptor inhibitor tocilizumab. The patient was successfully salvaged with baricitinib during the IL-6 inhibition period, despite the life-threatening hyperinflammatory complication. The report suggests baricitinib may be an effective rescue option for macrophage activation syndrome complicating adult-onset Still’s disease when IL-6 blockade is ongoing.

Nishisaka K, Ueda Y, Shirasugi I et al. · Modern rheumatology case reports · (2026) · View on PubMed ↗

Inhibition of p65 nuclear translocation in decidual stromal cells underlies COS-induced supraphysiologic estrogen impairment of uNK cell function which drives placental abnormalities.

The study examined how controlled ovarian stimulation (COS)-associated supraphysiologic estrogen impairs uterine natural killer (uNK) cell function in a mouse model, focusing on inhibition of p65 (NF-κB) nuclear translocation in decidual stromal cells and using pyrrolidine dithiocarbamate (PDTC) as a mechanistic intervention. The key finding was that blocking p65 nuclear translocation in decidual stromal cells underlies COS-induced estrogen-driven dysfunction of uNK cells, leading to placental abnormalities. This mechanistic link identifies the p65/NF-κB axis in decidual stromal cells as a potential therapeutic target to mitigate ART-related placental complications.

Yu H, Mu H, Xiong Y et al. · Journal of translational medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Mesenchymal stem cells reverse ovarian dysfunction by inhibiting autophagy in polycystic ovary syndrome mice.

The study tested whether human umbilical cord mesenchymal stromal cells (Huc-MSCs) reverse ovarian dysfunction in dehydroepiandrosterone (DHEA)-induced polycystic ovary syndrome (PCOS) mice by inhibiting autophagy, assessing effects on ovulation, sex hormones, and estrous cycling. Huc-MSC treatment improved ovarian function and restored reproductive parameters while suppressing autophagy-related dysregulation in the PCOS model. These results support MSC-based therapy as a potential autophagy-targeted approach for treating PCOS-associated ovarian dysfunction.

Liu Q, Zhan L, Kong L et al. · Stem cell research & therapy · (2026) · View on PubMed ↗ · Free PDF ↗

Medicolegal autopsy reconstruction of a medication-related adverse event trajectory in a psychiatric inpatient with diabetes: a case report.

This medicolegal case report studied a 47-year-old Japanese woman with bipolar disorder, insomnia, and long-standing type 2 diabetes mellitus in a psychiatric inpatient setting to reconstruct a medication-related adverse event trajectory. By integrating nursing record review, postmortem investigation, and toxicology, the authors identified the sequence leading to clinically significant metabolic deterioration that was initially nonspecific. The report highlights the value of structured medicolegal reconstruction to detect and attribute adverse drug events in high-risk psychiatric inpatients with diabetes.

Tsutsumi H, Sasao A, Hirata K et al. · Journal of medical case reports · (2026) · View on PubMed ↗ · Free PDF ↗

---

Infectious Disease & Host-Pathogen Mechanisms

Low DYNLL1 Resists Porphyromonas gingivalis-Induced Epithelial Jamming-Like State.

This study examined how low DYNLL1 affects epithelial recovery during Porphyromonas gingivalis challenge in the context of periodontal disease. Using a genome-wide CRISPR-Cas9 screen, the authors identified Dynein Light Chain LC8-Type 1 (DYNLL1) as a central mediator of the pathogen-induced epithelial jamming-like state, and low DYNLL1 conferred resistance to this pathological transition. Scientifically, it implicates DYNLL1-dependent host pathways in junctional epithelium remodeling failure and suggests a potential target to improve periodontal regeneration.

Li Q, Li J, Tao D et al. · Journal of dental research · (2026) · View on PubMed ↗

The New Vaccine Surveillance Network: 25 years of active, population-based surveillance for pediatric infectious diseases in the United States.

This methods-and-impact report described the New Vaccine Surveillance Network (NVSN), a CDC-established, multi-site active surveillance system for pediatric infectious diseases in the United States over 25 years. NVSN prospectively collects clinical, epidemiologic, and laboratory data from children presenting with acute respiratory infections (ARI) and acute gastroenteritis (AGE) across multiple care settings, enabling estimates of disease burden and vaccine effectiveness. Its significance is that long-term, population-based surveillance has quantified pediatric infectious disease burden and supported evaluation of licensed pediatric vaccines.

Payne DC, Weinberg GA, Halasa NB et al. · Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · (2026) · View on PubMed ↗

Rickettsia massiliae and its public health significance across Palearctic and Oriental regions: a scoping review.

This scoping review summarized evidence on Rickettsia massiliae across Palearctic and Oriental regions, focusing on transmission via arthropod vectors (ticks, fleas, lice), diagnostic methods, phylogenetic placement, human case reports, preventive measures, and geographic distribution. It consolidates what is known about how the spotted fever group pathogen circulates and how it is detected and prevented across these regions. The review supports public health surveillance and risk assessment by clarifying current knowledge gaps and informing vector-borne rickettsiosis preparedness.

Obaid MK, Yuchun C, Shehla S et al. · Infectious diseases of poverty · (2026) · View on PubMed ↗ · Free PDF ↗

Cardiomyocyte-enriched OTUD5 alleviates septic cardiomyopathy by promoting NLRP3 deubiquitination and inhibiting NLRP3 inflammasome activation.

This experimental study investigated cardiomyocyte-enriched OTUD5 as a therapeutic target in septic cardiomyopathy using primary neonatal rat cardiomyocytes exposed to lipopolysaccharide (LPS) and nigericin to model pyroptosis. It found that OTUD5 promotes NLRP3 deubiquitination and inhibits NLRP3 inflammasome activation, with OTUD5 cardiomyocyte-specific knockout worsening septic injury while OTUD5 enrichment alleviated inflammatory cell death readouts (IL-1β ELISA, Western blot, PI staining, CCK-8, LDH). The results identify the OTUD5–NLRP3 axis as a mechanistic driver of septic cardiomyopathy and a potential molecular target to reduce inflammasome-mediated damage.

Jiang Y, Jia Z, Zheng Z et al. · Clinical and translational medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Bioinspired microcapsule reactor with engineered probiotics for IBD therapy.

This preclinical study developed a core-shell bioinspired microcapsule reactor (MY-E@SS) delivering engineered probiotics for inflammatory bowel disease (IBD) therapy, addressing limitations of probiotic gastric acid survival and intestinal targeting. The bionic shell enabled safe gastrointestinal delivery, and at inflamed intestinal sites the bacteria sensed the pathological microenvironment and released an anti-inflammatory payload to improve disease outcomes. The approach supports a translational strategy for targeted, environment-responsive probiotic therapy in IBD.

Xu M, Du Y, Feng G · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Vancomycin-stressed Staphylococcus aureus extracellular vesicles hijack macrophage autophagy to enhance bacterial intracellular survival.

This experimental study investigated how vancomycin-stressed Staphylococcus aureus extracellular vesicles affect macrophage autophagy to enhance intracellular bacterial survival. It found that subinhibitory vancomycin promotes S. aureus survival within macrophages by hijacking macroautophagy/autophagy, including exacerbation of autophagic flux blockade, using in vitro and in vivo models. Scientifically, it suggests a mechanism for vancomycin treatment failure in MRSA bloodstream infections and identifies host autophagy as a potential therapeutic target to improve outcomes.

Lu B, Chang W, Liu X et al. · Autophagy · (2026) · View on PubMed ↗

Acute Appendicitis at Stem Cell Infusion During Autologous Transplantation for HIV-Associated Diffuse Large B-cell Lymphoma: A Case Report.

This case report studied acute appendicitis occurring during autologous hematopoietic stem cell transplantation (ASCT) in a 39-year-old man with HIV-associated diffuse large B-cell lymphoma (DLBCL). The key finding was that appendicitis can present during the transplant period with diagnostic overlap with conditioning-related gastrointestinal toxicity and neutropenic enterocolitis. The clinical significance is that clinicians should consider appendicitis in transplant patients with evolving abdominal symptoms to avoid misattribution to expected treatment toxicities.

El Mousadik M, Bousokri A, Tazi T et al. · Cureus · (2026) · View on PubMed ↗ · Free PDF ↗

Outcomes, prognostic factors, and the role of intracranial pressure monitoring in severe community-acquired bacterial meningitis: a multicenter retrospective cohort study.

This multicenter retrospective cohort study across 26 French ICUs (2012–2023) examined mechanically ventilated adults with severe community-acquired bacterial meningitis to determine 90-day outcomes, predictors of unfavorable neurological outcome, and the prognostic role of invasive intracranial pressure (ICP) monitoring. It focused on whether invasive ICP monitoring is associated with prognosis and identified factors linked to unfavorable neurological outcome at day 9 (details truncated in the abstract). The significance is that it informs ICU management decisions about monitoring strategies in a population with high mortality and disability.

Poirier C, Terzi N, Roesch N et al. · The Lancet regional health. Europe · (2026) · View on PubMed ↗ · Free PDF ↗

Orally administered biomimetic nanovesicles engineered with FGF2 orchestrate mucosal healing and microbiome remodeling in inflammatory bowel disease.

This work engineered orally administered biomimetic nanovesicles by loading fibroblast growth factor 2 (FGF2) into outer membrane vesicles (OMV/FGF2) secreted by FGF2-engineered Gram-negative bacteria to treat inflammatory bowel disease. In inflammatory bowel disease models, OMV/FGF2 promoted mucosal healing and remodeled the gut microbiome, overcoming FGF2’s degradation barrier during gastrointestinal transit. The approach suggests a clinically translatable oral delivery strategy for regenerative FGF2 signaling that also targets dysbiosis.

Yi M, Luo J, Abdo E et al. · Materials today. Bio · (2026) · View on PubMed ↗ · Free PDF ↗

---

Thrombosis, VTE/PE & Anticoagulation/Devices

Colorectal anastomotic safety assessment using ICG fluorescence and flexible endoscopy (COLOSSEUM): a global survey of 1367 surgeons.

This global Delphi-like survey studied colorectal surgeons worldwide (n=1367 from 80 countries) to characterize real-world use of indocyanine green (ICG) fluorescence and flexible endoscopy (FE) for assessing colorectal anastomotic perfusion and integrity. Surgeons showed substantial intersurgeon and institutional variability in how ICG and FE were applied for anastomotic safety assessment. These findings highlight the need for standardized, evidence-informed recommendations to reduce practice heterogeneity and potentially improve outcomes after colorectal anastomosis.

Belvedere A, Licardie E, Sochorova D et al. · Surgical endoscopy · (2026) · View on PubMed ↗

Rivaroxaban Then Aspirin vs. Aspirin Alone after Total Hip or Knee Arthroplasty.

In a multicenter, double-blind randomized trial after total hip or total knee arthroplasty, patients received either 81 mg aspirin or 10 mg oral rivaroxaban daily for the first 5 days, followed by 81 mg aspirin daily for 9 additional days after knee arthroplasty or 30 additional days after hip arthroplasty. The study compared rivaroxaban-then-aspirin versus aspirin alone for venous thromboembolism prevention and safety outcomes in this postoperative population. Clinically, the results address whether an initial short course of rivaroxaban is necessary or whether aspirin monotherapy is sufficient after arthroplasty.

Shivakumar S, Matino D, Zukor D et al. · The New England journal of medicine · (2026) · View on PubMed ↗

YEARS Algorithm for Diagnosis of Suspected Pulmonary Embolism in Patients With Cancer: A Randomized Clinical Trial.

In the Hydra randomized clinical trial, the YEARS algorithm was tested against a strategy of computed tomographic pulmonary angiography (CTPA) only to rule out acute pulmonary embolism (PE) in patients with active cancer. The key finding was the comparative safety and efficiency of YEARS-based triage versus immediate CTPA-only approaches, with blinded central adjudication of outcomes. The clinical significance is that it evaluates whether a guideline-friendly clinical prediction rule can safely reduce unnecessary imaging in cancer-associated suspected PE.

Akerboom B, Martens ESL, Stals MAM et al. · JAMA · (2026) · 1 citations · View on PubMed ↗

Clinical Recovery Without Recanalization in Iron Deficiency Anemia-Associated Cerebral Venous Thrombosis: A Case Report.

This case report studied cerebral venous thrombosis (CVT) associated with iron deficiency anemia (IDA) in a 45-year-old woman using CT, MRI, and MR venography. The key finding was clinical recovery without recanalization of the thrombosed right transverse sinus despite imaging evidence of persistent occlusion. This is scientifically and clinically significant because it suggests that symptom improvement in IDA-associated CVT may not always require radiographic recanalization, informing follow-up and prognostication.

Hoshi S, Moriwaki T, Mochida H · Cureus · (2026) · View on PubMed ↗ · Free PDF ↗

Outcomes in venous thromboembolism with retained vs removed inferior vena cava filters: an analysis from the Registro Informatizado de Enfermedad TromboEmbólica.

Using the international RIETE registry, this study analyzed outcomes in patients with acute venous thromboembolism who received retrievable inferior vena cava (IVC) filters, comparing retained versus removed filter status and accounting for anticoagulation use. From day 90 onward, clinical outcomes were stratified by filter status and anticoagulation, addressing long-term risks of filter retention. The findings inform guideline implementation by quantifying outcome differences tied to whether retrievable IVC filters are actually removed.

Cohen O, Santagata D, Kenet G et al. · Research and practice in thrombosis and haemostasis · (2026) · View on PubMed ↗ · Free PDF ↗

---

---

Generated automatically on July 14, 2026 from PubMed’s trending articles. Summaries are AI-generated; always consult the original publication for clinical or research decisions.